Craig Ritchie

List of Publications by Year
in descending order

54	1,953	279798	276875
papers	citations	23	41
		h-index	g-index

65	65	65	3144
all docs	docs citations	times ranked	citing authors

#	ARTICLE	IF	CITATIONS
1	Remote data collection speech analysis and prediction of the identification of Alzheimer's disease biomarkers in people at risk for Alzheimer's disease dementia: the Speech on the Phone Assessment (SPeAk) prospective observational study protocol. BMJ Open, 2022, 12, e052250.	1.9	7
2	Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review. European Journal of Neuroscience, 2022, 56, 5650-5713.	2.6	4
3	The European Prevention of Alzheimer's Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer's Disease Dementia. , 2022, , 190-206.		1
4	Impact of cerebral blood flow and amyloid load on SUVR bias. EJNMMI Research, 2022, 12, 29.	2.5	6
5	The Open-Access European Prevention of Alzheimer's Dementia (EPAD) MRI dataset and processing workflow. NeuroImage: Clinical, 2022, 35, 103106.	2.7	9
6	Inherited risk of dementia and the progression of cerebral small vessel disease and inflammatory markers in cognitively healthy midlife adults: the PREVENT-Dementia study. Neurobiology of Aging, 2021, 98, 124-133.	3.1	13
7	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimer's and Dementia, 2021, 17, 1189-1204.	0.8	44
8	Proximity to dementia onset and multi-modal neuroimaging changes: The prevent-dementia study. NeuroImage, 2021, 229, 117749.	4.2	10
9	Developing an Explainable Machine Learning-Based Personalised Dementia Risk Prediction Model: A Transfer Learning Approach With Ensemble Learning Algorithms. Frontiers in Big Data, 2021, 4, 613047.	2.9	31
10	Resting-state brain connectivity in healthy young and middle-aged adults at risk of progressive Alzheimer's disease. Neuroscience and Biobehavioral Reviews, 2021, 129, 142-153.	6.1	18
11	I think, therefore I forget – using experimental simulation of dementia to understand functional cognitive disorders. CNS Spectrums, 2020, 25, 511-518.	1.2	9
12	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. Alzheimer's Research and Therapy, 2020, 12, 8.	6.2	12
13	Involving research participants in a pan-European research initiative: the EPAD participant panel experience. Research Involvement and Engagement, 2020, 6, 62.	2.9	6
14	Cognitive Functions as Predictors of Alzheimer's Disease Biomarker Status in the European Prevention of Alzheimer's Dementia Cohort. Journal of Alzheimer's Disease, 2020, 74, 1203-1210.	2.6	7
15	NuBrain: UK consortium for optimal nutrition for healthy brain ageing. Nutrition Bulletin, 2020, 45, 223-229.	1.8	9
16	Multi-method genome- and epigenome-wide studies of inflammatory protein levels in healthy older adults. Genome Medicine, 2020, 12, 60.	8.2	30
17	Measuring multimorbidity beyond counting diseases: systematic review of community and population studies and guide to index choice. BMJ, The, 2020, 368, m160.	6.0	103
18	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.	0.8	29

#	Article	IF	Citations
19	THE EUROPEAN PREVENTION OF ALZHEIMERâ€™S DEMENTIA (EPAD) LONGITUDINAL COHORT STUDY: BASELINE DATA RELEASE V500.0. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-7.	2.7	31
20	Minocycline 200â€‰mg or 400â€‰mg versus placebo for mild Alzheimerâ€™s disease: the MADE Phase II, three-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-62.	0.7	10
21	Genome and epigenome wide studies of neurological protein biomarkers in the Lothian Birth Cohort 1936. Nature Communications, 2019, 10, 3160.	12.8	42
22	Associations Between Multimorbidity and Cerebrospinal Fluid Amyloid: A Cross-Sectional Analysis of the European Prevention of Alzheimerâ€™s Dementia (EPAD) V500.0 Cohort. Journal of Alzheimer's Disease, 2019, 71, 703-711.	2.6	5
23	Protocol for a conversation-based analysis study: PREVENT-ED investigates dialogue features that may help predict dementia onset in later life. BMJ Open, 2019, 9, e026254.	1.9	18
24	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimerâ€™s disease: study protocol for a randomised controlled trial (ELAD study). Trials, 2019, 20, 191.	1.6	127
25	Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimerâ€™s disease. BMJ Open, 2019, 9, e024498.	1.9	18
26	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.8	37
27	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimer's and Dementia, 2018, 14, 837-842.	0.8	20
28	Cerebral small vessel disease in middle age and genetic predisposition to lateâ€onset Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 253-258.	0.8	14
29	European Prevention of Alzheimerâ€™s Dementia Longitudinal Cohort Study (EPAD LCS): study protocol. BMJ Open, 2018, 8, e021017.	1.9	72
30	Secondary prevention of Alzheimerâ€™s dementia: neuroimaging contributions. Alzheimer's Research and Therapy, 2018, 10, 112.	6.2	46
31	Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial. Lancet Psychiatry,the, 2018, 5, 553-563.	7.4	53
32	Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT. Health Technology Assessment, 2018, 22, 1-62.	2.8	5
33	The midlife cognitive profiles of adults at high risk of lateâ€onset Alzheimer's disease: The PREVENT study. Alzheimer's and Dementia, 2017, 13, 1089-1097.	0.8	57
34	Functional neuroimaging findings in healthy middle-aged adults at risk of Alzheimerâ€™s disease. Ageing Research Reviews, 2017, 36, 88-104.	10.9	38
35	Structural neuroimaging in preclinical dementia: From microstructural deficits and grey matter atrophy to macroscale connectomic changes. Ageing Research Reviews, 2017, 35, 250-264.	10.9	48
36	Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project. Alzheimer's and Dementia, 2017, 13, 186-195.	0.8	85

#	ARTICLE	IF	CITATIONS
37	Better together for better dementia research and care. Lancet Psychiatry,the, 2016, 3, 503-504.	7.4	0
38	Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. Lancet Psychiatry,the, 2016, 3, 179-186.	7.4	171
39	The Clinical Picture of Alzheimerâ€™s Disease in the Decade Before Diagnosis. Journal of Clinical Psychiatry, 2016, 77, e305-e311.	2.2	50
40	Is lateâ€ onset Alzheimer's disease really a disease of midlife?. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2015, 1, 122-130.	3.7	82
41	Boosting translational research on Alzheimer's disease in Europe: The Innovative Medicine Initiative AD research platform. Alzheimer's and Dementia, 2015, 11, 1121-1122.	0.8	15
42	Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research. Alzheimer's Research and Therapy, 2015, 7, 31.	6.2	77
43	SouvenaidÂ®: A new approach to management of early Alzheimer's disease. Journal of Nutrition, Health and Aging, 2014, 18, 291-299.	3.3	19
44	The PREVENT research programme â€“ A novel research programme to identify and manage midlife risk for dementia: the conceptual framework. International Review of Psychiatry, 2013, 25, 748-754.	2.8	26
45	The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease. BMJ Open, 2012, 2, e001893.	1.9	93
46	The association between personality disorder and an act of deliberate self harm in the older person. International Psychogeriatrics, 2011, 23, 299-307.	1.0	4
47	Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3Â½ years duration. International Journal of Geriatric Psychiatry, 2010, 25, 411-418.	2.7	18
48	Management of self-harm in older people. Psychiatric Bulletin, 2009, 33, 423-425.	0.3	0
49	A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. International Journal of Geriatric Psychiatry, 2006, 21, 171-179.	2.7	30
50	Atlas of Psychiatric Pharmacotherapy By SHILOH, NUTT AND WEIZMAN Martin Dunitz, London, U.K., 2000, reprinted 2002, U.K. Â£32.50.Paperback, pp. 235, ISBN 1 853 179 345. International Psychogeriatrics, 2005, 17, 139-140.	1.0	2
51	Metal-protein attenuating compounds and Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2004, 13, 1585-1592.	4.1	60
52	Metaanalysis of Randomized Trials of the Efficacy and Safety of Donepezil, Galantamine, and Rivastigmine for the Treatment of Alzheimer Disease. American Journal of Geriatric Psychiatry, 2004, 12, 358-369.	1.2	114
53	The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. International Journal of Geriatric Psychiatry, 2003, 18, 432-440.	2.7	79
54	Patient or client? The opinions of people attending a psychiatric clinic. Psychiatric Bulletin, 2000, 24, 447-450.	0.3	23